Skip to main content

Table 3 Healthcare utilization and medical costs of patients with ATTR-CM (PPPM)

From: Clinical manifestation, economic burden, and mortality in patients with transthyretin cardiac amyloidosis

  Pre-cohort entry date,
mean (SD)
Post-cohort entry date, mean (SD) P-value
Number of inpatient admissions 0.10 (0.12) 0.38 (0.55) < 0.001
 ER 0.01 (0.03) 0.03 (0.11) 0.040
 ICU 0.01 (0.04) 0.09 (0.27) < 0.001
Length of hospital stay (days) 1.12 (2.78) 5.72 (9.08) < 0.001
Number of outpatient visits 2.63 (2.10) 2.60 (1.96) 0.837
 ER 0.02 (0.06) 0.05 (0.25) 0.085
Follow-up costs $400 ($588) $1864 ($2773) < 0.001
 Inpatient $313 ($567) $1730 ($2767) < 0.001
 Outpatient $87 ($76) $134 ($154) < 0.001
  1. ATTR-CM Transthyretin amyloid cardiomyopathy, ER Emergency room, ICU Intensive care unit, PPPM Per patient per month, SD Standard deviation